Ichimaru N, Natori Y, Alloway RR, Wojciechowski D, et al. Phase 2, Randomized, Double-blind, Placebo-controlled Study of Fiztasovimab (NPC-21) for Kidney Transplant Recipients at High Risk of Cytomegalovirus Infection (LionHeart21). Transplantation 2024 Nov 6. doi: 10.1097/TP.0000000000005260.
PMID: 40072882